Regarding the translation of these results into clinicopathological routine, we suggest that the responsible pathologist reports SATB2 loss by stating the percentage of SATB2 expressing cancer cells, ideally combined with the notion that a significantly reduced expression of SATB2 has been associated with a poorer clinical outcome. Here, SATB2 is linked to cancer.